Efficacy of weekly paclitaxel in patients with advanced gastric cancer refractory to docetaxel-based chemotherapy

Gastric Cancer

Volumn 15, Issue 4, 2012, Pages 427-432

  Ando, Takayuki ^a   Hosokawa, Ayumu ^a   Kajiura, Shinya ^a   Itaya, Yuko ^a   Ueda, Akira ^a   Fujinami, Haruka ^a   Nishikawa, Jun ^a   Kobayashi, Takashi ^b   Horikawa, Naoki ^b   Tsukioka, Yuji ^b   Yabushita, Kazuhisa ^b   Note, Masayuki ^b   Ogawa, Kohei ^a   Sugiyama, Toshiro ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b Kohseiren Takaoka Hospital   (Japan)

Author keywords

Chemotherapy; Cross resistance; Docetaxel; Gastric cancer; Weekly paclitaxel

Indexed keywords

CISPLATIN; DOCETAXEL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SENSORY NEUROPATHY; STOMACH CANCER; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; STOMACH NEOPLASMS; TAXOIDS; TREATMENT OUTCOME;

EID: 84870343214     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-011-0135-0     Document Type: Article

References (28)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24: 2137-50.
2. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999;49: 33-64.
3. Power DG, Kelsen DP, Shah MA. Advanced gastric cancer - slow but steady progress. Cancer Treat Rev. 2010;36: 384-92.
4. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010;28: 1547-53.
5. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol. 2009;10: 1063-9.
6. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9: 215-21.
7. Narahara H, Iishi H, Imamura H, Tsuburaya A, Chin K, Imamoto H, et al. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer. 2011;14: 72-80.
8. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24: 4991-7.
9. Ajani JA, Fairweather J, Dumas P, Patt YZ, Pazdur R, Mansfield PF. Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J Sci Am. 1998;4: 269-74.
10. Cascinu S, Graziano F, Cardarelli N, Marcellini M, Giordani P, Menichetti ET, et al. Phase II study of paclitaxel in pretreated advanced gastric cancer. Anticancer Drugs. 1998;9: 307-10.
11. Ohtsu A, Boku N, Tamura F, Muro K, Shimada Y, Saigenji K, et al. An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol. 1998;21: 416-9.
12. Yamada Y, Shirao K, Ohtsu A, Boku N, Hyodo I, Saitoh H, et al. Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol. 2001;12: 1133-7.
13. Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 2008;26: 1642-9.
14. Kodera Y, Ito S, Mochizuki Y, Fujitake S, Koshikawa K, Kanyama Y, et al. A phase II study of weekly paclitaxel as secondline chemotherapy for advanced gastric cancer (CCOG0302 study). Anticancer Res. 2007;27: 2667-71.
15. Shimoyama R, Yasui H, Boku N, Onozawa Y, Hironaka S, Fukutomi A, et al. Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin. Gastric Cancer. 2009;12: 206-11.
16. Bissery MC, Guenard D, Gueritte-Voegelein F, Lavelle F. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res. 1991;51: 4845-52.
17. Verweij J, Clavel M, Chevalier B. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol. 1994;5: 495-505.
18. Valero V, Jones SE, Von Hoff DD, Booser DJ, Mennel RG, Ravdin PM, et al. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol. 1998;16: 3362-8.
19. Aravantinos G, Bafaloukos D, Fountzilas G, Christodoulou C, Papadimitriou C, Pavlidis N, et al. Phase II study of docetaxel- vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer. Ann Oncol. 2003;14: 1094-9.
20. Sella A, Yarom N, Zisman A, Kovel S. Paclitaxel, estramustine and carboplatin combination chemotherapy after initial docetaxel- based chemotherapy in castration-resistant prostate cancer. Oncology. 2009;76: 442-6.
21. Lin YC, Chang HK, Wang CH, Chen JS, Liaw CC. Single-agent docetaxel in metastatic breast cancer patients pre-treated with anthracyclines and paclitaxel: partial cross-resistance between paclitaxel and docetaxel. Anticancer Drugs. 2000;11: 617-21.
22. Yonemori K, Katsumata N, Uno H, Matsumoto K, Kouno T, Tokunaga S, et al. Efficacy of weekly paclitaxel in patients with docetaxel-resistant metastatic breast cancer. Breast Cancer Res Treat. 2005;89: 237-41.
23. Sawaki M, Ito Y, Hashimoto D, Mizunuma N, Takahashi S, Horikoshi N, et al. Paclitaxel administered weekly in patients with docetaxel-resistant metastatic breast cancer: a single-center study. Tumori. 2004;90: 36-9.
24. Taguchi T, Aihara T, Takatsuka Y, Shin E, Motomura K, Inaji H, et al. Phase II study of weekly paclitaxel for docetaxel-resistant metastatic breast cancer in Japan. Breast J. 2004;10: 509-13.
25. Taguchi T, Sakata Y, Kanamaru R, Kurihara M, Suminaga M, Ota J, et al. Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: a Japanese Cooperative Study Group trial (group A). Gan To Kagaku Ryoho. 1998;25: 1915-24.
26. Fujii M. Chemotherapy for advanced gastric cancer: ongoing phase III study of S-1 alone versus S-1 and docetaxel combination (JACCRO GC03 study). Int J Clin Oncol. 2008;13: 201-5.
27. Koizumi W, Nakayama N, Tanabe S, Sasaki T, Higuchi K, Nishimura K, et al. A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601). Cancer Chemother Pharmacol (Epub ahead of print).
28. Matsuda G, Kunisaki C, Makino H, Fukahori M, Kimura J, Sato T, et al. Phase II study of weekly paclitaxel as a second-line treatment for S-1-refractory advanced gastric cancer. Anticancer Res. 2009;29: 2863-7.